ACS Chemical Biology
Page 10 of 11
We acknowledge Y. Huang from Central South University, (17) Schujman, G. E., Choi, K. H., Altabe, S., Rock, C. O. and
1
2
3
4
5
6
7
8
9
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
3
3
3
3
3
3
3
3
3
3
4
4
4
4
4
4
4
4
4
4
5
5
5
5
5
5
5
5
5
5
6
Changsha, China, for providing us with platencin.
de Mendoza, D. (2001) Response of Bacillus subtilis to
cerulenin and acquisition of resistance. J Bacteriol. 183 (10),
3032-40.
REFERENCES
(18) Park, H. S., Yoon, Y. M., Jung, S. J., Kim, C. M., Kim, J.
M. and Kwak, J. (2007) Antistaphylococcal activities of
CG400549, a new bacterial enoyl-acyl carrier protein reductase
(1) WHO, Antimicrobial resistance: Global report on
surveillance. (2014). World Health Organization: Geneva,
Switzerland.
(FabI) inhibitor. J Antimicrob Chemother. 60 (3), 568-74.
(
2) Johnson, A. P., Uttley, A. H., Woodford, N. and George, R.
(19) Escaich, S., Prouvensier, L., Saccomani, M., Durant, L.,
Oxoby, M., Gerusz, V., Moreau, F., Vongsouthi, V., Maher, K.,
Morrissey, I. and Soulama-Mouze, C. (2011) The MUT056399
inhibitor of FabI is a new antistaphylococcal compound.
Antimicrob Agents Chemother. 55 (10), 4692-7.
C. (1990) Resistance to vancomycin and teicoplanin: an
emerging clinical problem. Clin Microbiol Rev. 3 (3), 280-91.
0
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
6
7
8
9
0
(3) Tsay, J. T., Oh, W., Larson, T. J., Jackowski, S. and Rock,
C. O. (1992) Isolation and characterization of the β-ketoacyl-
acyl carrier protein synthase III gene (fabH) from Escherichia
coli K-12. J Biol Chem. 267 (10), 6807-14.
(20) Hafkin, B., Kaplan, N. and Murphy, B. (2015) Efficacy and
safety of AFN-1252, the first Staphylococcus-specific
antibacterial agent, in the treatment of acute bacterial skin and
skin structure infections, including those in patients with
significant comorbidities. Antimicrob Agents Chemother. 60
(3), 1695-701.
(4) Qiu, X., Choudhry, A. E., Janson, C. A., Grooms, M.,
Daines, R. A., Lonsdale, J. T. and Khandekar, S. S. (2005)
Crystal structure and substrate specificity of the β-ketoacyl-acyl
carrier protein synthase III (FabH) from Staphylococcus aureus.
Protein Sci. 14 (8), 2087-94.
(21) Wang, J., Kodali, S., Sang, H. L. and Galgoci, A. (2007)
(
5) Chiou-Yan, L. and Cronan, J. E. (2003) β-ketoacyl-acyl
Discovery of platencin, a dual FabF and FabH inhibitor with in
vivo antibiotic properties. Proc Natl Acad Sci U S A. 104 (18),
7612-6.
carrier protein synthase III (FabH) is essential for bacterial fatty
acid synthesis. J Biol Chem. 278 (51), 51494-503.
(
6) Choi, K. H., Heath, R. J. and Rock, C. O. (2000) β-ketoacyl-
(22) Pishchany, G., Mevers, E., Ndousse-Fetter, S., Horvath, D.
J., Paludo, C. R., Silva-Junior, E. A., Koren, S., Skaar, E. P.,
Clardy, J. and Kolter, R. J. (2018) Amycomicin is a potent and
specific antibiotic discovered with a targeted interaction screen.
Proc Natl Acad Sci U S A. 115 (40), 10124-9.
acyl carrier protein synthase III (FabH) is a determining factor
in branched-chain fatty acid biosynthesis. J Bacteriol. 182 (2),
365-70.
(7) Lu, X. Y., Tang, J., Zhang, Z. and Ding, K. (2015) Bacterial
β-ketoacyl-acyl carrier protein synthase III (FabH) as a target
for novel antibacterial agents design. Curr Med Chem. 22 (5),
651-67.
(23) Yao, J. and Rock, C. O. (2015) How bacterial pathogens
eat host lipids: implications for the development of fatty acid
synthesis therapeutics. J Biol Chem. 290 (10), 5940-6.
(8) Luo, Y., Yang, Y. S., Fu, J. and Zhu, H. L. (2012) Novel
FabH inhibitors: a patent and article literature review (2000--
2012). Expert Opin Ther Pat. 22 (11), 1325-36.
(24) Parsons, J. B., Frank, M. W., Chitra, S., Panatda, S. and
Rock, C. O. (2011) Metabolic basis for the differential
susceptibility of Gram-positive pathogens to fatty acid synthesis
inhibitors. Proc Natl Acad Sci U S A. 108 (37), 15378-83.
(9) Song, H., Ao, G.Z. and Li, H.Q. (2014) Novel FabH
inhibitors: an updated article literature review (July 2012 to
June 2013). Expert Opin Ther Pat. 24 (1), 19-27.
(25) Parsons, J. B., Frank, M. W., Rosch, J. W. and Rock, C. O.
(2013) Staphylococcus aureus fatty acid auxotrophs do not
proliferate in mice. Antimicrob Agents Chemother. 57 (11),
(10) Castillo, Y. P. and Perez, M. A. (2008) Bacterial β-
ketoacyl-acyl carrier protein synthase III (FabH): an attractive
target for the design of new broad-spectrum antimicrobial
agents. Mini Rev Med Chem. 8 (1), 36-45.
5
729-32.
(26) Fair, R. J. and Tor, Y. (2014) Antibiotics and bacterial
resistance in the 21st century. Perspect Medicin Chem. 6, 25-
6
4.
(11) Parsons, J. B. and Rock, C.O. (2013) Bacterial lipids:
Metabolism and membrane homeostasis. Prog Lipid Res. 52 (3),
(27) Tommasi, R., Brown, D. G., Walkup, G. K., Manchester,
J. I. and Miller, A. A. (2015) ESKAPEing the labyrinth of
antibacterial discovery. Nat Rev Drug Discov. 14 (8), 529-42.
2
49-76.
(12) Pawełczyk, J. and Kremer, L. (2014) The molecular
genetics of mycolic acid biosynthesis. Microbiol Spectr. 2 (4),
MGM2-0003-2013.
(28) Payne, D. J., Gwynn, M. N., Holmes, D. J. and Pompliano,
D. L. (2007) Drugs for bad bugs: confronting the challenges of
antibacterial discovery. Nat Rev Drug Discov. 6 (1), 29-40.
(13) Heath, R. J. and Rock, C. O. (2004) Fatty acid biosynthesis
as a target for novel antibacterials. Curr Opin Investig Drugs. 5
(29) Davies, C., Heath, R. J., White, S. W. and Rock, C. O.
(2000) The 1.8 A crystal structure and active-site architecture of
β-ketoacyl-acyl carrier protein synthase III (FabH) from
Escherichia coli. Structure. 8 (2), 185-95.
(2), 146-53.
(14) Wright, H. T. and Reynolds, K. A. (2007) Antibacterial
targets in fatty acid biosynthesis. Curr Opin Microbiol. 10 (5),
4
47-53.
(30) Marcella, A. M., Jing, F. and Barb, A. W. (2015)
Purification, preparation of holo- and malonyl-(acyl-carrier-
protein) in a manner suitable for analog development. Protein
Expr Purif. 115 (5), 39-45.
(15) Jukic, M., Gobec, S. and Sova, M. (2019) Reaching toward
underexplored targets in antibacterial drug design. Drug Dev
Res. 80 (1), 6-10.
(
16) Das, M., Sakha Ghosh, P. and Manna, K. (2016) A review
on platensimycin: a selective FabF Inhibitor. Int J Med Chem.
016, 9706753.
2
ACS Paragon Plus Environment